Phathom Pharmaceuticals, Inc. (PHAT)
| Market Cap | 857.85M |
| Revenue (ttm) | 204.89M |
| Net Income (ttm) | -157.30M |
| Shares Out | 79.43M |
| EPS (ttm) | -2.09 |
| PE Ratio | n/a |
| Forward PE | 29.34 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 808,179 |
| Open | 10.84 |
| Previous Close | 10.72 |
| Day's Range | 10.34 - 10.95 |
| 52-Week Range | 7.61 - 18.31 |
| Beta | 0.51 |
| Analysts | Strong Buy |
| Price Target | 23.70 (+119.44%) |
| Earnings Date | Aug 6, 2026 |
About PHAT
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-eros... [Read more]
Financial Performance
In 2025, Phathom Pharmaceuticals's revenue was $175.11 million, an increase of 216.93% compared to the previous year's $55.25 million. Losses were -$221.25 million, -33.82% less than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for PHAT stock is "Strong Buy." The 12-month stock price target is $23.7, which is an increase of 119.44% from the latest price.
News
Phathom Pharmaceuticals completes enrollment in pHalcon-EoE-201 clinical trial
Phathom Pharmaceuticals (PHAT) announced it has completed enrollment in its Phase 2 pHalcon-EoE-201 clinical trial evaluating Voquezna tablets as an investigational treatment for eosinophilic esophagi...
Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
This trial is the first large, placebo-controlled clinical trial of an acid suppression treatment in EoE Topline results for the double-blind 12-week treatment portion of the study are expected in Q4 ...
Phathom Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
VOQUEZNA adoption is accelerating in GI practices, with strong prescriber and patient satisfaction, and a focus on expanding both clinical and market access confidence. Revenue is growing rapidly, profitability is expected in Q3, and a phase II EoE trial could further boost growth and exclusivity.
Phathom Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
VOQUEZNA’s rapid adoption in gastroenterology is driving strong revenue growth, with a strategic focus on high-need patients and a path to profitability this year. Physician awareness is high, and future expansion into primary care and new GI assets is planned, leveraging long-term exclusivity and a robust sales force.
Needham pharmaceuticals analysts hold analyst/industry conference call
Pharmaceuticals Analysts discuss Phathom Pharmaceuticals’s (PHAT) Voquezna (vonoprazan) on an Analyst/Industry conference call to be held on May 27.
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointe...
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting
FLORHAM PARK, N.J., May 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointe...
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting
FLORHAM PARK, N.J., May 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointe...
Phathom Pharmaceuticals reports Q1 non-GAAP EPS (18c), consensus (19c)
Reports Q1 revenue $58.3M, consensus $56.81M. “In Q1, we more than doubled revenue compared to the prior year Q1. We have implemented our pivot to GI and the associated sales…
Phathom Pharmaceuticals still sees 2026 revenue $320M-$34M, consensus $332.04M
07:41 EDT Phathom Pharmaceuticals (PHAT) still sees 2026 revenue $320M-$34M, consensus $332.04M
Phathom Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue more than doubled year-over-year, driven by strong VOQUEZNA adoption among GI specialists and an expanded sales force. Guidance for 2026 is maintained, with operating profitability targeted by Q3 and positive cash flow in 2027.
Phathom Pharmaceuticals Earnings release: Q1 2026
Phathom Pharmaceuticals released its Q1 2026 earnings on April 30, 2026, summarizing the period's financial results.
Phathom Pharmaceuticals Quarterly report: Q1 2026
Phathom Pharmaceuticals has published its Q1 2026 quarterly earnings report on April 30, 2026.
Phathom Pharmaceuticals Slides: Q1 2026
Phathom Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 30, 2026.
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
FLORHAM PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastroin...
Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026
Management to host conference call on Thursday, April 30, 2026, at 8:00 am EDT FLORHAM PARK, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical ...
Phathom Pharmaceuticals Transcript: 25th Annual Needham Virtual Healthcare Conference
VOQUEZNA’s focused GI strategy is driving strong revenue growth, with 2026 set as a pivotal year for profitability and cash flow. The company’s capital structure is now sustainable, and long-term growth will be supported by expanding into primary care and leveraging first-mover advantage.
Phathom Pharmaceuticals Proxy statement: Proxy filing
Phathom Pharmaceuticals filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Phathom Pharmaceuticals Proxy statement: Proxy filing
Phathom Pharmaceuticals filed a proxy statement on April 7, 2026, providing details for shareholder voting and corporate governance matters.
Phathom Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Jenna Davidner upgraded Phathom Pharmaceuticals (PHAT) to Overweight from Equal Weight with a price target of $18, up from $16. The company’s Q1 trends are “lighter,” but the…
Phathom Pharmaceuticals management to meet with Cantor
Meeting to be held in London on March 23, Stockholm March 24 and Zurich March 25 hosted by Cantor.
Phathom Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Leadership implemented a strategic pivot to gastroenterology, cut operating expenses by 50%, and restructured finances to support sustainable growth. The company projects strong revenue growth, targets a $1 billion market in GI, and expects exclusivity until at least 2033.
Phathom Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
A focused GI specialist strategy has driven strong growth for VOQUEZNA, with revenue rising to $175 million and a clear path to $1–2 billion in annual sales. Regulatory exclusivity extends to 2032, and financial discipline supports profitability by H2 2026.
Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim
Guggenheim raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $25 from $20 and keeps a Buy rating on the shares. The firm, which continues to be “encouraged” by…
Phathom Pharmaceuticals price target raised to $13 from $12 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $13 from $12 and keeps a Neutral rating on the shares after its Q4 earnings beat. The firm…